136 related articles for article (PubMed ID: 38670300)
21. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
22. Patterns and Patients' Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With Type 2 Diabetes: A Population-based Cohort Study.
Campbell DB; Campbell DJT; Au F; Beall RF; Ronksley PE; Chew DS; Ogundeji Y; Manns BJ; Hemmelgarn BR; Tonelli M; Quinn AE
Can J Diabetes; 2023 Feb; 47(1):58-65.e2. PubMed ID: 36184371
[TBL] [Abstract][Full Text] [Related]
23. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
[TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
Fralick M; Colacci M; Thiruchelvam D; Gomes T; Redelmeier DA
Diabetes Obes Metab; 2021 Apr; 23(4):950-960. PubMed ID: 33336894
[TBL] [Abstract][Full Text] [Related]
25. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS; Bhatt DL; Hameed I; Anker SD; Cheng AYY; Hernandez AF; Jones WS; Khan MS; Petrie MC; Udell JA; Friede T; Butler J
Lancet Diabetes Endocrinol; 2024 Jul; 12(7):447-461. PubMed ID: 38768620
[TBL] [Abstract][Full Text] [Related]
26. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
[TBL] [Abstract][Full Text] [Related]
27. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
[TBL] [Abstract][Full Text] [Related]
28. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
[TBL] [Abstract][Full Text] [Related]
29. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Starr JA; Pinner NA
Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
[TBL] [Abstract][Full Text] [Related]
30. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology.
Mai Z; Li H; Chen G; Chen E; Liu L; Lun Z; Lai W; Zhou C; Yu S; Liu J; Chen S; Chen J; Liu Y
Cardiovasc Drugs Ther; 2022 Aug; 36(4):713-726. PubMed ID: 34028657
[TBL] [Abstract][Full Text] [Related]
31. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
Teo YH; Yoong CSY; Syn NL; Teo YN; Cheong JYA; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
Eur J Clin Pharmacol; 2021 Oct; 77(10):1453-1464. PubMed ID: 33942132
[TBL] [Abstract][Full Text] [Related]
32. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
33. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
Imran H; Nester W; Elgendy IY; Saad M
Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
[TBL] [Abstract][Full Text] [Related]
34. Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study.
Chang HC; Chen YY; Kuo TT; Lin YJ; Chien KL; Chang HY; Hung CL; Chung FP
J Am Heart Assoc; 2024 Apr; 13(8):e032397. PubMed ID: 38591334
[TBL] [Abstract][Full Text] [Related]
35. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
36. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
[TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
38. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
[TBL] [Abstract][Full Text] [Related]
39. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
